This is the message they are attempting to convey, but I would take not the 4,000 figure too literally. We’ll know how selective ACH-1625 is for the HCV protease vs host proteases when we see the clinical data on side effects. Ditto for IDIX’s slide that asserts no inhibition of host proteases by IDX136/316.
I don’t know the answer, but it’s many more than eight.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.